STOP-HE study of OCR-002 in hospitalized cirrhotic patients with acute hepatic encephalopathy

Phase 2, randomised, double-blind trial in hepatic encephalopathy (HE), hyperammonemia and Cirrhosis comparing OCR-002 + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Efficacy of OCR-002 for treatment of an acute hepatic encephalopathy episode and Safety and tolerability of OCR-002. Started Jun 2016; status: active, not recruiting.